Hydrochlorothiazide

Generic Name: Hydrochlorothiazide

Brand Names: Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac

Drug Type: Small Molecule

Chemical Formula: C_₇H_₈ClN_₃O_₄S_₂

CAS Number: 58-93-5

Unique Ingredient Identifier: 0J48LPH2TH

Background: Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication: Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions: Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke

Clinical Trials

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: losartan potassium
Drug: hydrochlorothiazide (HCTZ)

First Posted Date: 2009-04-23

Last Posted Date: 2015-08-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 122

Registration Number: NCT00886600

Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets

First Posted Date: 2009-03-31

Last Posted Date: 2009-03-31

Lead Sponsor: Ranbaxy Laboratories Limited

Target Recruit Count: 40

Registration Number: NCT00872235

Locations: 🇮🇳
Ranbaxy CPU, New Delhi, India

Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fasting Conditions

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets

First Posted Date: 2009-03-31

Last Posted Date: 2009-03-31

Lead Sponsor: Ranbaxy Laboratories Limited

Target Recruit Count: 64

Registration Number: NCT00872781

Locations: 🇮🇳
Ranbaxy Clinical Pharmacology Unit, Noida,, Uttar Pradesh, India

Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Isosorbide mononitrate (ISMN)
Drug: Hydrochlorothiazide (HCTZ)

First Posted Date: 2009-03-30

Last Posted Date: 2015-07-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 64

Registration Number: NCT00871871

Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease

Not Applicable

Completed

Conditions: Type 2 Diabetes Mellitus
Vascular Disease

Interventions: Drug: Hydrochlorothiazide + potassium
Other: Placebo
Drug: Spironolactone

First Posted Date: 2009-03-19

Last Posted Date: 2017-06-14

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 69

Registration Number: NCT00865124

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Renin Profiling in Selection of Initial Antihypertensive Drug

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: olmesartan, hydrochlorothiazide, amlodipine
Drug: hydrochlorothiazide (HCTZ) or olmesartan

First Posted Date: 2009-02-03

Last Posted Date: 2012-04-19

Lead Sponsor: The Louis & Rachel Rudin Foundation

Target Recruit Count: 185

Registration Number: NCT00834600

Locations: 🇺🇸
Ralph Yung, MD, Bronx, New York, United States
🇺🇸
Albert Einstein College of Medicine - GCRC, Bronx, New York, United States
🇺🇸
Lincoln Medical and Mental Health Center, Bronx, New York, United States

and more 2 locations